VSTM2A and colorectal carcinoma: After adjustment for potential confounding factors, lower VSTM2A methylation was found to be an independent risk factor for overall survival in CRC patients by multivariate Cox regression analysis (RR 1.67 (95% CI 1.01 to 2.73), P = 0.044; Table S5).